Vibrocil drops nasal

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

dimethindene (dimethindene maleate), phenylephrine

Доступна с:

GlaxoSmithKline Consumer Healthcare SARL

код АТС:

R01BA53

ИНН (Международная Имя):

dimethindene (dimethindene maleate), phenylephrine

дозировка:

0,25mg/ml+ 2,5mg/ml

Фармацевтическая форма:

drops nasal

Штук в упаковке:

15ml glass vial

Тип рецепта:

OTC

Статус Авторизация:

Registered

Дата Авторизация:

2022-12-08

Характеристики продукта

Regulatory Affairs
Vibrocil Nasal Drops
Dimetindene maleate 0.025% + Phenylephrine base 0.25%
SUMMARY OF PRODUCT CHARACTERISTICS
CONFIDENTIAL
Page 2
1.
NAME OF THE MEDICINAL PRODUCT
................................................................... 3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
......................................... 3
3.
PHARMACEUTICAL FORM
.......................................................................................
3
4.
CLINICAL PARTICULARS
..........................................................................................
3
4.1.
Therapeutic indications
.......................................................................................
3
4.2.
Posology and method of administration
............................................................. 3
4.3.
Contra-indications
..............................................................................................
4
4.4.
Special warnings and precautions for use
........................................................... 4
4.5.
Interactions with other medicinal products and other forms of
interaction ........ 4
4.6.
Pregnancy and lactation
......................................................................................
5
4.7.
Effects on ability to drive and use machines
...................................................... 4
4.8.
Undesirable effects
.............................................................................................
5
4.9.
Overdose
.............................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES
........................................................................
6
5.1.
Pharmacodynamic properties
..............................................................................
6
5.2.
Pharmacokinetic properties
................................................................................
6
5.3
Preclinical safety data
.........................................................................................
7
6.
PHARM